ARTICLE | Clinical News
Starlix nateglinide regulatory update
January 2, 2001 8:00 AM UTC
The FDA granted marketing approval for Starlix, a D-phenylalanine derivative, to treat Type II diabetes as monotherapy and in combination with metformin. The product is under review in Europe and is m...